Cytosorbents (CTSO) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to -$306.7 million.
- Cytosorbents' Retained Earnings fell 346.45% to -$306.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$306.7 million, marking a year-over-year decrease of 346.45%. This contributed to the annual value of -$304.0 million for FY2024, which is 731.38% down from last year.
- As of Q3 2025, Cytosorbents' Retained Earnings stood at -$306.7 million, which was down 346.45% from -$303.5 million recorded in Q2 2025.
- Over the past 5 years, Cytosorbents' Retained Earnings peaked at -$200.8 million during Q1 2021, and registered a low of -$306.7 million during Q3 2025.
- Its 5-year average for Retained Earnings is -$263.5 million, with a median of -$268.0 million in 2023.
- In the last 5 years, Cytosorbents' Retained Earnings plummeted by 1951.76% in 2022 and then tumbled by 335.97% in 2025.
- Quarter analysis of 5 years shows Cytosorbents' Retained Earnings stood at -$221.2 million in 2021, then fell by 14.83% to -$254.0 million in 2022, then dropped by 11.53% to -$283.3 million in 2023, then fell by 7.31% to -$304.0 million in 2024, then dropped by 0.89% to -$306.7 million in 2025.
- Its Retained Earnings was -$306.7 million in Q3 2025, compared to -$303.5 million in Q2 2025 and -$305.5 million in Q1 2025.